{"schemaVersion":"cwiki-fiche-1.0","identifiers":{"inchiKey":"ORTVDISIJXKUAV-FCHUYYIVSA-N","prefName":"JWH-051","symbol":"JWH-051","iupacName":"[(6aR,10aR)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-9-yl]methanol","aliases":["Deoxy-HU210"],"cas":null,"pubchemCid":"9799540","chebiId":null,"smiles":"CCCCCCC(C)(C)C1=CC2=C(C=C1)[C@@H]3CC(=CC[C@H]3C(O2)(C)C)CO","molecularFormula":"C25H38O2","molecularWeight":370.6,"xrefs":{"pubchem":"https://pubchem.ncbi.nlm.nih.gov/compound/9799540"}},"classification":{"family":"scra","familyLabel":"Synthetic cannabinoid (SCRA)","origin":"synthetic","originLabel":"Synthétique","structuralClassFr":null},"originSynthesis":{"heading":"Origin (pharmaceutical research → illicit market)","summaryFr":"No known biosynthetic pathway: no living organism is recorded as producing the molecule in the databases consulted, which results from organic synthesis. Its manufacture is described here by chemical class only.","originNote":"Fully synthetic molecule: no plant is recorded as producing it in the databases consulted, cannabis included. It belongs to the 1-deoxy-Δ8-THC series developed at Clemson University by John W. Huffman and his team, whose work aims to relate chemical structure to activity at cannabinoid receptors.","discovered":""},"pharmacology":{"summaryFr":"JWH-051, or 1-deoxy-11-hydroxy-Δ8-THC-dimethylheptyl, is a synthetic cannabinoid of the 1-deoxy-Δ8-THC series developed by John W. Huffman at Clemson. Huffman et al. reported in 2010 an affinity of 1.2 ± 0.1 nM for CB1 and 0.032 ± 0.019 nM for CB2. On isolated rodent tissue it inhibits electrically evoked contractions (Griffin et al., 1997), and Klein et al. (1998) call it a CB2 agonist. In mice, its antinociceptive effect is incompletely blocked by a CB1 antagonist after central injection. No human data were found, and no human dose can be inferred from this work. In France it is classed as a narcotic under the clause covering derivatives of the benzo[c]chromene nucleus, although the molecule is not named.","receptorSummaryFr":"Agonist at the CB1 and CB2 receptors, with very high affinity for each. The constants published by Huffman et al. in 2010 are 1.2 ± 0.1 nM for CB1 and 0.032 ± 0.019 nM for CB2, meaning a higher affinity for CB2 than for CB1. In isolated rodent tissue assays, the molecule inhibits electrically evoked contractions of the mouse vas deferens and of the guinea pig myenteric plexus; this inhibition is reduced by the antagonist SR141716A only in the myenteric plexus, which suggests action through CB1 in that tissue and mainly through CB2-type receptors in the vas deferens (Griffin et al., 1997). In cultured mouse splenocytes, it increases IL-4 production as THC does, an effect the authors attribute to the CB2 receptor (Klein et al., 1998).","binding":[{"target":"CB1","efficacy":"full_agonist","relativeActivity":93,"reported":"Ki 1,2 ± 0,1 nM (Huffman et coll., 2010)","confidence":"medium"},{"target":"CB2","efficacy":"full_agonist","relativeActivity":97,"reported":"Ki 0,032 ± 0,019 nM (Huffman et coll., 2010)","confidence":"medium"}],"references":[{"label":"Huffman et coll., analogues 1-bromo-1-désoxy-Δ8-THC pour CB2, Bioorg Med Chem 2010","pmid":"20943404","doi":null,"url":"https://pubmed.ncbi.nlm.nih.gov/20943404/"},{"label":"Huffman, revue sur les ligands sélectifs du récepteur CB2, Curr Pharm Des 2000","pmid":"10903395","doi":null,"url":"https://pubmed.ncbi.nlm.nih.gov/10903395/"},{"label":"Griffin et coll., récepteurs CB2 sur terminaisons nerveuses périphériques, Eur J Pharmacol 1997","pmid":"9450616","doi":null,"url":"https://pubmed.ncbi.nlm.nih.gov/9450616/"},{"label":"Klein et coll., récepteurs cannabinoïdes et réseau des cytokines, Adv Exp Med Biol 1998","pmid":"9666274","doi":null,"url":"https://pubmed.ncbi.nlm.nih.gov/9666274/"},{"label":"Welch et coll., blocage de l'antinociception centrale par SR141716A, J Pharmacol Exp Ther 1998","pmid":"9732392","doi":null,"url":"https://pubmed.ncbi.nlm.nih.gov/9732392/"},{"label":"ANSM, liste consolidée des substances classées comme stupéfiants, mise à jour du 16 février 2026","pmid":null,"doi":null,"url":"https://ansm.sante.fr/uploads/2026/02/17/20260217-stupefiants-liste-consolidee.pdf"},{"label":"INCB, Green List 2026 (conventions de 1971)","pmid":null,"doi":null,"url":"https://www.incb.org/incb/uploads/documents/Psychotropics/forms/greenlist/2026/2510307E.pdf"},{"label":"PubChem, CID 9799540","pmid":null,"doi":null,"url":"https://pubchem.ncbi.nlm.nih.gov/compound/9799540"}]},"pharmacokinetics":null,"metabolism":null,"detection":null,"subjectiveEffects":{"profile":[{"key":"calm","label":"Calm","description":"Relaxation of body and mind; reduced mental noise without marked drowsiness.","intensity":8},{"key":"focus","label":"Clarity","description":"Sustained attention and clear thinking; functional lucidity, not euphoria.","intensity":5},{"key":"sleep","label":"Sleep","description":"Sedative effect: aids sleep onset and the continuity of deep sleep.","intensity":10},{"key":"appetite","label":"Appetite","description":"Stimulation of hunger and of taste appreciation (the “munchies” effect).","intensity":8},{"key":"uplift","label":"High","description":"Euphoria and sensory intensity; altered perception of time and space.","intensity":8}],"doseRanges":null,"humanDataCharacterised":false},"indications":{"approvedMedicines":[]},"harmProfile":{"unstudiedBanner":true,"bannerTextFr":"Aucune dose humaine caractérisée : données animales / in vitro uniquement. Profil d'effet, marge de sécurité et toxicité aiguë non documentés en clinique humaine.","toxicologyFr":null},"legal":{"scheduleStatus":"unscheduled","scheduleLabel":"Unscheduled","frScheduleStatus":"controlled-clause","tiers":[{"jurisdiction":"international","jurisdictionLabel":"International","label":null,"reference":null,"url":null,"effectiveDate":null,"lastVerified":"2026-05-01","supersededBy":null},{"jurisdiction":"eu","jurisdictionLabel":"Union européenne","label":"No harmonised European Union control measure targets this molecule according to the sources consulted; control is national. At international level, it is not named in the INCB Green List 2026, including among the listed tetrahydrocannabinol isomers.","reference":null,"url":null,"effectiveDate":null,"lastVerified":"2026-05-01","supersededBy":null},{"jurisdiction":"fr","jurisdictionLabel":"France","label":"Not named in the consolidated French list of narcotics updated on 16 February 2026, but covered by a generic clause. The decision of 22 May 2024 classes as narcotics « any substance derived from the benzo[c]chromene nucleus » whether or not substituted at the positions it lists. JWH-051 meets each condition: benzo[c]chromene nucleus present, alkyl chain at position 3, two alkyl groups at position 6, hydroxyalkyl group at position 9, and position 1 free, which the clause permits. It is not one of the substances excluded by the clause (cannabinol, cannabinolic acid, THCV, THCA). HU-210, its analogue carrying a hydroxyl at position 1, is itself named in the same list.","reference":null,"url":null,"effectiveDate":null,"lastVerified":"2026-05-01","supersededBy":null}],"sourcesFr":"EUR-Lex, UNODC, CND, ANSM, IUPHAR/BPS, ChEBI, EUDA."},"references":[{"label":"Huffman et coll., analogues 1-bromo-1-désoxy-Δ8-THC pour CB2, Bioorg Med Chem 2010","pmid":"20943404","doi":null,"url":"https://pubmed.ncbi.nlm.nih.gov/20943404/"},{"label":"Huffman, revue sur les ligands sélectifs du récepteur CB2, Curr Pharm Des 2000","pmid":"10903395","doi":null,"url":"https://pubmed.ncbi.nlm.nih.gov/10903395/"},{"label":"Griffin et coll., récepteurs CB2 sur terminaisons nerveuses périphériques, Eur J Pharmacol 1997","pmid":"9450616","doi":null,"url":"https://pubmed.ncbi.nlm.nih.gov/9450616/"},{"label":"Klein et coll., récepteurs cannabinoïdes et réseau des cytokines, Adv Exp Med Biol 1998","pmid":"9666274","doi":null,"url":"https://pubmed.ncbi.nlm.nih.gov/9666274/"},{"label":"Welch et coll., blocage de l'antinociception centrale par SR141716A, J Pharmacol Exp Ther 1998","pmid":"9732392","doi":null,"url":"https://pubmed.ncbi.nlm.nih.gov/9732392/"},{"label":"ANSM, liste consolidée des substances classées comme stupéfiants, mise à jour du 16 février 2026","pmid":null,"doi":null,"url":"https://ansm.sante.fr/uploads/2026/02/17/20260217-stupefiants-liste-consolidee.pdf"},{"label":"INCB, Green List 2026 (conventions de 1971)","pmid":null,"doi":null,"url":"https://www.incb.org/incb/uploads/documents/Psychotropics/forms/greenlist/2026/2510307E.pdf"},{"label":"PubChem, CID 9799540","pmid":null,"doi":null,"url":"https://pubchem.ncbi.nlm.nih.gov/compound/9799540"}],"meta":{"slug":"jwh-051","url":"https://en.phytogrammes.com/wiki/jwh-051","lastVerified":"2026-05-01","dataUpdatedAt":"2026-10-13","confidence":"high","dataCompletenessPct":90,"disclaimerFr":"Contenu éditorial informatif, sans valeur d'avis médical ni juridique. Sources primaires citées par fiche. Réservé aux adultes."}}